此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Repository of Phase Signals for Algorithm Development and Testing in CAD in CHINA (CADChina)

2019年7月25日 更新者:Shanghai Zhongshan Hospital

Repository of Phase Signals for Algorithm Development and Testing in Subjects With Coronary Artery Disease in China

The primary objective of this study is to build a repository of resting cardiac phase space signals from eligible subjects using the Phase Signal Recorder (PSR) prior to coronary angiography for the purposes of machine-learning and testing algorithms developed by Analytics 4 Life. Male and Female subjects will be uniquely and consecutively enrolled into one group to support populating a repository of phase signals.

研究概览

地位

未知

详细说明

Analytics 4 Life (A4L) is a medical information technology company that uses advanced signal processing techniques for the purposes of assessing and diagnosing disease. A4L is currently focused on developing a non-invasive solution for the assessment of significant coronary artery disease using the cardiac Phase Space Tomography Analysis (cPSTA) System. Through proprietary variable extraction to define phase space signals as metrics in mathematical terms and machine learned formulas, A4L has developed a cost-effective solution to collect and analyze phase signals as data indicative of cardiac performance. The cPSTA System passively reconstructs and displays images from this data using topological data analysis (TDA) to provide a computationally tractable method of interrogating the complex physiological processes of the heart with the intent to understand and characterize the cardiac tissue properties.

A4L has providing the Phase Signal Recorder (PSR) to the sponsor for use in this study. The primary objective of this study is to collect resting phase signals from eligible subjects using the Phase Space Recorder (PSR) prior to coronary angiography for the purpose of machine learning and testing an algorithm developed to assess the presence of significant coronary artery disease (CAD).The definition of significant CAD, which is well established in the literature, is either the presence of a stenosis ≥50% by angiography or reduced blood flow of <0.80as measured by Fractional Flow Rate (FFR) or instantaneous free-wave ratio (iFR) <0.89.Each subject's CAD status will be assessing the presence of significant CAD in the major coronary arteries including the left main artery (LMA), left anterior descending artery (LAD), circumflex artery (LCX), and the right coronary artery (RCA) and their distributions.

Accurately assessing the presence or absence of CAD and evaluating other physiologic measures is vital to the assessment of cardiac health/illness. As such, the following additional assessments are planned to support further support goal: establishing a ROC curve for the primary objective to describe a full range of sensitivity and specificity trade-offs; and, developing and testing machine-learned algorithms to validate a clinically relevant sensitivity and specificity for the identification of significant CAD specific to perfusion regions (LAD, LCX, and RCA).

研究类型

介入性

注册 (预期的)

500

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients ≥ 18 years old
  2. Meets criteria for coronary angiography
  3. Scheduled to undergo cardiac catheterization with coronary angiography
  4. Ability to understand the requirements of the study and to provide written informed consent

Exclusion Criteria:

  1. Prior coronary artery bypass grafting (CABG)
  2. Prior heart valve replacement
  3. Previous sustained or paroxysmal atrial or ventricular arrythmia;
  4. Infiltrative myocardial disease (amyloid, sarcoid, right ventricular dysplasia);
  5. Presence of cardiac implantable electronic device (CIED), including implantable cardioverter defibrillator (ICD), pacemaker (PM), implantable loop recorders and other monitors
  6. Implantable Neuro-stimulators
  7. Congenital Heart Disease
  8. Pregnant or breast feeding
  9. Currently taking any Type IA, IC or III antiarrhythmics
  10. Any history of amiodarone use
  11. Clinically significant chest deformity (e.g., pectus excavatum or pectus carinatum)
  12. Breast implants
  13. Neuromuscular Disease if the condition results in tremor or muscle fasciculations

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:cPSTA GROUP
Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo cardiac Phase Space Tomography Analysis (cPSTA) signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
其他名称:
  • PSR

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
positive coronary artery disease
大体时间:7 day after index procedure
significant stenosis measured by coronary angiography
7 day after index procedure
positive cardiac Phase Space Tomography Analysis
大体时间:7 day after index procedure
positive result measured by cardiac Phase Space Tomography Analysis
7 day after index procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Juying Qian, M.D.、Shanghai Zhongshan Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2019年8月1日

初级完成 (预期的)

2020年6月1日

研究完成 (预期的)

2020年7月1日

研究注册日期

首次提交

2019年7月21日

首先提交符合 QC 标准的

2019年7月25日

首次发布 (实际的)

2019年7月26日

研究记录更新

最后更新发布 (实际的)

2019年7月26日

上次提交的符合 QC 标准的更新

2019年7月25日

最后验证

2019年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅